← Back to Search

Calcium Channel Blocker

Topical diltiazem + lidocaine for Rectal Disease

Phase 2 & 3
Waitlist Available
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

This trial is testing two creams, Diltiazem and Nifedipine, on patients with long-lasting anal tears. These creams help by relaxing the muscles around the tear, allowing better blood flow and faster healing.

Eligible Conditions
  • Rectal Disease
  • Nipple Injury
  • Anal Fissure
  • Rectal Bleeding

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Anal bleeding
Perianal irritation
Perianal pain

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Topical diltiazem + lidocaineExperimental Treatment1 Intervention
Group II: Topical nifedipine + lidocaineActive Control1 Intervention

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
808 Previous Clinical Trials
883,959 Total Patients Enrolled
~97 spots leftby Nov 2025